* AB SCIENCE *
2001 - IDF
Paris
www.ab-science.com Discovery, Drugs
Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases
Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals
Clients: Prescribers, Veterinarians
ines.delov@ab-science.com
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Guy (Laurent)
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€)
note (September 2011) : sales are derived from masitinib in veterinary practice | Turnover (M€) : 2.3 (2010), 0.53 (2009)
Total funding (M€) : 30.0
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .04 | Financing (interest loan) : 7.5 M€, by existing shareholders (eurobonds) | DEBT | [9 years] |
| 2010 .10 | Clinical trial (phase III) for masitinib in 3 types of cancers (pancreatic, mastocytosis and gastro-intestinal), in EU and USA (beginning, in total 9 trials) | CLIN | [9 years] |
| 2010 .05 | Listing on Euronext Paris : 31.6 M€ (55.0 M€ expected) | PBO | [8 years] |
| 2008 .09 | Registration : positive opinion from EMEA for lead compound masitinib in the treatment of canine mast cell tumor | MKTG | [7 years] |
| 2007 .05 | Court : legal prosecution against Medicen, Paris Pôle de Compétitivité, with a claim of 125 M€ | LEGAL | [5 years] |
| 2001 .07 | Company founded by Alain Moussy | ORGF | [0 year] | Actualisation / Updating: 20-Sep-2011 |
|
